Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet ...

As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening

Related Keywords

United States ,Americans ,Austin Murtagh ,Sarah Oconnell ,Kitty Yale ,Exchange Commission ,Akero Therapeutics Inc ,Twitter ,Nasdaq ,Linkedin ,Lancet Gastroenterology ,South San ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Region ,